Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Akzo Nobel reveals new dopamine antagonists

March 14, 1997

NMDA antagonists claimed by Novartis

March 14, 1997

Antiparkinson Rx from Sumitomo in pivotal European trials

March 13, 1997

Somatostatin receptor antagonists prepared by Novartis

March 13, 1997

First approval for naratriptan

March 12, 1997

Pfizer initiates clinical trial in panic disorder

March 12, 1997

Bayer claims potassium channel modulators

March 12, 1997

Cytogen seeks Canadian approval for Quadramet

March 11, 1997

Painless local dermal anesthesia now available

March 11, 1997

Eurand develops taste-masked form of ketoprofen

March 11, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Roche secures CE mark for Alzheimer’s blood test
BioWorld
Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...